US FDA approves Vanda Pharmaceuticals' motion sickness drug
30/12/2025 23:16
Dec 30 (Reuters) - The U.S. Food and Drug Administration has approved Vanda Pharmaceuticals' VNDA.O drug for the prevention of vomiting induced by motion, the company said on Tuesday. (Reporting by Siddhi Mahatole and Puyaan Singh in Bengaluru; Editing by Shilpi Majumdar) ((siddhi.mahatole@thomsonreuters.com;))
Recent news on Viatris
See all newsBrief: Viatris Receives U.S. FDA Approval For Ryzumvi® For The Treatment Of Presbyopia
Pacira BioSciences jumps on $1.65 billion Viatris buyout deal
Deals of the day-Mergers and acquisitions
Brief: Viatris - Pacira To Pay Viatris $62 Million Termination Fee Under Specified Circumstances
Pacira BioSciences jumps on $1.65 billion Viatris buyout deal